Skip to main content

Esteve, PharmaMar, Almirall and Ordesa participate in some of the 18 projects approved by the CENIT

By 26 de November de 2009November 18th, 2020No Comments
< Back to news

Esteve, PharmaMar, Almirall and Ordesa participate in some of the 18 projects approved by the CENIT

The Ministry of Science And Innovation has announced this week the 18 public-private cooperation projects of R+D that have been selected in the 5th Call of the National Strategic Consortiums in Technical Research Programme (CENIT-E). Three of these projects pertain to companies that carry out their activity in the biotech and biomedical field in Catalonia: Neogenius Pharma –an association of economic interest comprised by Almirall, Esteve and Palau Pharma-; Pharma Mar –of the Zeltia group-; and the Quiron Hospital Group. Some of the companies that participate in these projects, such as Pharma Mar, Esteve and Almirall, have offices at the Barcelona Science Park.

Specifically, Pharma Mar will research new strategies based on biomarkers for the detection of cancer, its prognosis, response prediction and the development of new treatments, while Neogenius Pharma will focus its efforts on the discovery of drugs to combat arthrosis.

, Ordesa, a company which is doing part of its research at PCB, is also participating in SENIFOOD, a project that was selected in this 5th Call with the objective of developing food specifically suited for seniors.

Out of the 251 companies that are participating in the projects that have been approved, 51% are SMEs and 49% are large companies. The CENIT will subsidize 200 million Euros, of which 50 million correspond to the Spanish Plan to Stimulate the Economy and Employment (Plan E), promoted by the central Government.

The CENIT programme aims to generate new knowledge that can be of use to the creation of new products, processes, services or to the integration of technologies of strategic interest. For this reason, the projects that have been selected are aimed at promoting planned research in technological fields of the future with ample international reach. The fields of biotechnology, health and food already account for 39% of approved projects and are on a par with the fields of energy, the environment and climate change.